Navigation Links
New protocol developed to decontaminate human fetal tissues used for cell transplantation
Date:7/22/2013

Putnam Valley, NY. -- The use of central nervous system fetal tissues derived from routine elective abortions to provide stem cells for transplantation procedures aimed at restoring damage done by neurodegenerative diseases is an established therapy. However, fetal tissue microbial contaminants have been known to cause brain infections in cell transplantation recipients. Now, a research team from Germany has developed a "washing" technique that decontaminates the fetal tissues from which stem cells are derived.

The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct1020piroth.

"Fetal neural tissue transplantation has become a potential treatment option for patients suffering from neurodegenerative diseases such as Parkinson's disease (PD) and Huntington's disease (HD)," explained study co-author Dr. Guido Nikkah of the Department of Neurosurgery, Erlangen University Clinic, Erlangen, Germany. "However, in Europe neural transplantation of fetal tissue must be performed in accordance with guidelines on "Good Manufacturing Processes," which means that aspects of microbiological safety have to be investigated in detail."

According to the researchers, aborted fetal human tissues carry the risk of bacterial contamination from the abortion process and this is the contributing factor to the subsequent risk of infection to cell recipients. The researchers noted that prior to their study it was not clear whether fetal tissue contamination, or subsequent surgical contamination during cell transplantation normally had the greatest impact as potential contributing factors to microbial infection in hosts.

Their study revealed a wide range of microbial contamination in fetal tissues that could cause infections. 47.7 % of the fetal tissues they sampled were positive for microbial infection. They also found that the risk of bacterial infection was higher than the risk of fungal infection.

To prevent microbial infection in cell transplantation hosts, the researchers developed and tested a microbial "washing" technique. In laboratory tests using rats as transplantation hosts, the technique has been shown to eliminate microbial contamination. Based on the technique's success in decontaminating fetal tissue cells transplanted into laboratory animals, the washing technique was subsequently used in clinical practice.

"To date, more than 350 PD and approximately 100 HD patients have received primary fetal grafts, and so far no contamination has been reported," said Dr. Nikkah.

The researchers noted that although the risk of infection is very low after their procedure, they still recommend antibiotic prophylaxis.

"Detection of a relevant microbial contamination within the narrow time-window prior to transplantation remains difficult," concluded the authors. "While contamination of the transportation fluid is not an exclusion criterion for tissue transplantation, detection of contamination after washing steps is critical."

"The potentially deleterious impact of microbial contamination on the use of cells or tissues for transplantation is an important health factor that cannot be ignored." said Dr. Shinn-Zong Lin, professor of Neurosurgery and superintendent at the China Medical University Hospital, Beigang, Taiwan. "Procedures to reduce the likelihood of contamination such as that described within this paper are therefore of great importance."


'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. Lower dosage CT-guided lung biopsy protocol maintains quality, minimizes exposure
2. New protocol recommendations for measuring soil organic carbon sequestration
3. NYSCF scientists develop new protocol to ready induced pluripotent stem cell clinical application
4. JISC Collections purchases SpringerProtocols
5. Mini-CT scanner developed as a teaching tool
6. Blossom end rot plummets in Purdue-developed transgenic tomato
7. The first chemical circuit developed
8. Grassroots approach to conservation developed
9. Composite nanofibers developed by Penn scientists next chapter in orthopaedic biomaterials
10. Electronic nose prototype developed
11. New long-term antimicrobial catheter developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... Report Highlights The global biosurgery ... billion in 2016 at a compound annual growth rate ... Includes - An overview of the global market for ... from 2015 and 2016, and projections of compound annual ... market on the basis of product type, source, application, ...
(Date:2/3/2017)... , Feb. 3, 2017  Texas Biomedical Research Institute ... Larry Schlesinger as the Institute,s new President ... Biomed effective May 31, 2017. He is currently the Chair ... of the Center for Microbial Interface Biology at Ohio State ... as the new President and CEO of Texas Biomed," said ...
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, a ... emerging technology, announces the availability of a new report, Sensors ... Continue Reading ... ... and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets ...
Breaking Biology News(10 mins):
(Date:2/27/2017)... 27, 2017 Four US Biotech ... today, and they are: Anthera Pharmaceuticals Inc. (NASDAQ: ANTH), ... Inc. (NASDAQ: PACB), and Conatus Pharmaceuticals Inc. (NASDAQ: ... Trends, market observers are growing more bullish on the ... reforms to free cash held overseas for tax reason ...
(Date:2/27/2017)... , ... February 27, 2017 , ... The Catalyst ... a few in the Midwest offering premix services and private label organic services. , ... laying hens, according Jos Zamzow, chief operating officer of Dynamite Marketing, which owns the ...
(Date:2/24/2017)... ... ... Delpor, Inc. (Delpor), a biotechnology company focused on drug delivery, today announced ... for the further advancement of the company’s 3-month olanzapine product ( DLP-119 ). The ... therapeutic levels of olanzapine for a period of 3 months., “We are honored and ...
(Date:2/24/2017)... SAN FRANCISCO , Feb. 24, 2017 ... that is developing a new category of therapeutics, announced ... trial of SB-030 in peripheral artery disease. The trial ... locally administered single-use therapeutic, in the reduction of restenosis ... reached this critical development milestone for SB-030," said ...
Breaking Biology Technology: